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1.Technology Description-Researchers discovered that when the Varicella Zoster Virus (VZV) 
reactivates from latency in the body,  the virus is consistently present in saliva before the 
appearance of skin lesions. A small saliva sample is mixed with a specialized reagent in a test kit.  
If the virus is present in the saliva sample, the mixture turns a red color.  The sensitivity and 
specificity emanates from an antibody-antigen reaction. This technology is a rapid, non-invasive, 
point of-of-care testing kit for detecting the virus from a saliva sample. The device is easy to use 
and can be used in clinics and in remote locations to quickly detect VZV and begin treatment 
with antiviral drugs. 
2.Market Opportunity- RST Bioscience will be the first and only company to market a rapid, 
same day test kit for the detection of VZV in saliva.  The RST detection test kit will have several 
advantages over existing, competitive technology.  The test kit is self contained and laboratory 
equipment is not required for analysis of the sample. Only a single saliva sample is required to be 
taken instead of blood or cerebral spinal fluid. The test kit is portable, sterile and disposable after 
use. RST detection test kits require no electrical power or expensive storage equipment and can 
be used in remote locations.  
3.Market Analysis- According to the CDC, it is estimated that 1 million cases of shingles occur 
each year in the U.S. with more than half over the age of sixty.  There is a high demand for rapid 
diagnostics by the public.  The point-of-care testing (POCT) market is growing faster than other 
segments of in vitro diagnostics.  According to a July 2007 InteLab Corporation industry report 
the overall market for POCT was forecast to increase from $10.3 billion in 2005 to $18.7 billion 
by 2011.  The market value of this test kit has not been determined. 
4.Competition- The VZV vaccine prevents 50% of cases and reduces neuralgia by 66%.  The 
most popular test detects VZV-specific IgM antibody in blood.  Other tests include running a 
sample in a polymerase chain reaction analyzer, enzyme immunoassay, latex agglutination,  
indirect fluorescent antibody and fluorescent antibody to membrane antigen assay. These 
existing tests require laboratory analysis by trained personnel, expensive equipment, invasive 
procedures and a longer period of time to obtain test results. 
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